Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical’s Phase 2 Clinical Trial

August 14, 2019 0 comments

About the Author

user

Related Posts

AIVITA Biomedical Announces Publication Comparing Clinical Outcomes in Patients Treated with AIVITA’s Immunotherapy and Other Immunotherapies

ROOT OF SKIN™ Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan

AIVITA Biomedical Announces Publication Concerning a Predictive Biomarker for Melanoma Patients Treated with the Company’s Platform Immunotherapy

AIVITA CEO Dr. Hans Keirstead Honored as One of Canada’s ‘Seven Wonderers’ at Beakerhead Festival

More From This Category

AIVITA Biomedical Announces Publication Comparing Clinical Outcomes in Patients Treated with AIVITA’s Immunotherapy and Other Immunotherapies

ROOT OF SKIN™ Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan

AIVITA Biomedical Announces Publication Concerning a Predictive Biomarker for Melanoma Patients Treated with the Company’s Platform Immunotherapy

AIVITA CEO Dr. Hans Keirstead Honored as One of Canada’s ‘Seven Wonderers’ at Beakerhead Festival